



09/04/01

09/04/01 09:14:15


PCT

JC05 Rec'd PCT/PTO 3 0 AUG 2001

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER PF-0673 USN
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TO BE ASSIGNED 09/914815
INTERNATIONAL APPLICATION NO. PCT/US00/05153	INTERNATIONAL FILING DATE 29 February 2000	PRIORITY DATE CLAIMED 01 March 1999
TITLE OF INVENTION LEUKOCYTE- AND BLOOD-ASSOCIATED PROTEINS		
APPLICANT(S) FOR DO/EO/US INCYTE PHARMACEUTICALS, INC.; LAL, Preeti; YUE, Henry; HILLMMAN, Jennifer L.; LU, Dyung Aina M.; BAUGHN, Mariah R.; TANG, Y. Tom; AZIMZAI, Yalda		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"><input checked="" type="checkbox"/> This is the FIRST submission of items concerning a filing under 35 U.S.C. 371.<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.<input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).<input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).<input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none"><input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau)<input type="checkbox"/> has been communicated by the International Bureau.<input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).<input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).<input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none"><input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).<input type="checkbox"/> have been communicated by the International Bureau.<input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.<input checked="" type="checkbox"/> have not been made and will not be made.<input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).<input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).<input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11 to 16 below concern document(s) or information included:		
<ol style="list-style-type: none"><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.<input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included.<input checked="" type="checkbox"/> A FIRST preliminary amendment, as follows:<p>Cancel in this application original claims 16, 19 and 22 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.</p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.<input type="checkbox"/> A substitute specification.<input type="checkbox"/> A change of power of attorney and/or address letter.<input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none">1) Transmittal Letter (2 pp, in duplicate)2) Return Postcard3) Express Mail Label No.: EL 856 148 018 US4) Request to Transfer		

JCS3 REC/PCT/PTO

30 AUG 2001

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/914815		INTERNATIONAL APPLICATION NO. PCT/US00/05153		ATTORNEY'S DOCKET NUMBER PF-0673 USN	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..\$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00 <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$690.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20 =	0	X \$ 18.00	\$	
Independent Claims	2 =	0	X \$ 80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$690.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$690.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$690.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$690.00	
				Amount to be Refunded:	\$
				Charged	\$
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>09-0108</u> in the amount of \$ <u>690.00</u> to cover the above fees c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>09-0108</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO INCYTE GENOMICS, INC 3160 Porter Drive Palo Alto, CA 94304					
SIGNATURE 					
NAME Diana Hamlet-Cox					
REGISTRATION NUMBER: 33,302					
DATE: <u>29</u> August 2001					

LEUKOCYTE- AND BLOOD-ASSOCIATED PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of leukocyte- and blood-associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of autoimmune/inflammatory disorders and cell proliferative disorders including cancer.

BACKGROUND OF THE INVENTION

The blood circulatory system is comprised of a variety of cell types, including leukocytes (white blood cells), red blood cells, and plasma. Leukocytes are part of the immune system and are responsible for immune responses. A critical feature of the immune response is recognition of antigens. Some leukocytes are activated through cell-mediated immune responses, and react with foreign antigens on the surface of other host cells. These antigens can be carried through the blood, and the levels of these antigens can be indicative of the progression of a particular disease or disorder. For example, in some cancers, the blood plasma may carry cell surface proteins such as tumor cell markers. Because of these and other interactions, critical information for diagnosis, treatment, and prevention of various diseases and disorders can be gained through an understanding of the nature and function of leukocyte- and blood-associated proteins.

The plethora of cell surface proteins associated with the circulatory system includes cellular signaling receptors and tumor antigens. One such tumor antigen detectable in blood serum is carcinoembryonic antigen (CEA). CEA is a well established glycoprotein marker of adenocarcinomas of the colon, pancreas, lung, breast, and ovary (Cotran, R. et al (1994), Robbins Pathological Basis of Disease 5th edition, W.B. Saunders Company, Philadelphia PA, pp. 300-301). CEA belongs to a small group of protein molecules like alpha-fetoprotein, prostate-specific antigen, and muclins such as CA-125 that are regularly monitored in the blood serum of cancer patients (Cotran, supra).

Leukocyte membrane proteins such as Fc receptor, interleukin-2 receptor, and other lymphokine receptors on lymphokine activated killer (LAK) cells are key cell membrane proteins involved in the immune response to tumors (Brostoff, J. et al. (1991) Clinical Immunology, Mosby, London, England, pp.20.8-20.12). Another membrane surface protein found on LAK cells, the V7 gene product, has a role in T cell activation. V7, a cell surface glycoprotein on antigen-activated T cells, monocytes, and granulocytes, has an extracellular domain that resembles immunoglobulin (Ig)-like domains, containing seven pairs of cysteine residues. V7 may be a new member of the Ig gene superfamily and have a functional role in the immune response (Ruegg, C. et al. (1995) J. Immunol. 154:44434-44443).

Cell surface membrane-bound microbial superantigens may have a role in the pathogenesis of autoimmune disorders. Examples are the human endogenous retroviral (HERV) superantigens. Cell surface expression of HERV derived superantigen by professional antigen-presenting cells such as macrophages and dendritic cells may lead to beta-cell destruction in the pancreas through systemic activation of autoreactive T cells (Conrad, B. et al. (1991) Cell 90:303-313).

Another class of circulatory system-associated cell surface molecules are the receptors associated with hemopoiesis. The binding of hemopoietic growth factors and cytokines to specific cell surface receptor proteins triggers intracellular signaling, resulting in the proliferation and differentiation of blood cell progenitors. These cell surface receptor proteins include interleukin-2 alpha and interleukin-2 beta, erythropoietin, and various colony stimulating factors. Each of these receptors is a transmembrane protein with an extracellular ligand-binding domain that is activated through direct interaction with its cognate ligand (Kaczmarek, R. and G. Jufti (1991) Blood Rev. 5:193-203).

The discovery of new leukocyte- and blood-associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of autoimmune/inflammatory disorders and cell proliferative disorders including cancer.

SUMMARY OF THE INVENTION

The invention features purified polypeptides, leukocyte- and blood-associated proteins, referred to collectively as "LBAP" and individually as "LBAP-1," "LBAP-2," "LBAP-3," "LBAP-4," and "LBAP-5." In one aspect, the invention provides an isolated polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-5.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5. In one alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:6-10.

WO 00/52161

PCT/US00/05153

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

10 The invention also provides a method for producing a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

20 Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5.

25 The invention further provides an isolated polynucleotide comprising a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:6-10, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:6-10, c) a polynucleotide sequence complementary to a), or d) a polynucleotide sequence complementary to b). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

30 Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:6-10, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide

WO 00/52161

PCT/US00/05153

sequence selected from the group consisting of SEQ ID NO:6-10, c) a polynucleotide sequence complementary to a), or d) a polynucleotide sequence complementary to b). The method comprises a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically
5 hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 30 contiguous nucleotides. In another alternative, the probe comprises at least 60 contiguous nucleotides.

10 The invention further provides a pharmaceutical composition comprising an effective amount of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, or d) an
15 immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, and a pharmaceutically acceptable excipient. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional LBAP, comprising administering to a patient in need of such treatment the pharmaceutical composition.

The invention also provides a method for screening a compound for effectiveness as an
20 agonist of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ
25 ID NO:1-5. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a pharmaceutical composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional LBAP, comprising
30 administering to a patient in need of such treatment the pharmaceutical composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, c)

WO 00/52161

PCT/US00/05153

a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, or d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a pharmaceutical composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional LBAP, comprising administering to a patient in need of such treatment the pharmaceutical composition.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:6-10, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

BRIEF DESCRIPTION OF THE TABLES

Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding LBAP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of LBAP.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding LBAP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze LBAP, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"LBAP" refers to the amino acid sequences of substantially purified LBAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of LBAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of LBAP either by directly interacting with LBAP or by acting on components of the biological pathway in which LBAP participates.

An "allelic variant" is an alternative form of the gene encoding LBAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding LBAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as LBAP or a polypeptide with at least one functional characteristic of LBAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding LBAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding LBAP. The encoded protein may also be "altered," and may contain deletions, insertions, or

substitutions of amino acid residues which produce a silent change and result in a functionally equivalent LBAP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of LBAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

10 The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

20 The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of LBAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of LBAP either by directly interacting with LBAP or by acting on components of the biological pathway in which LBAP participates.

25 The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind LBAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

30 The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures

on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide
5 nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell,
10 the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical
15 functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic LBAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" and "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the
20 complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which
25 depend upon binding between nucleic acid strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution.
30 Compositions comprising polynucleotide sequences encoding LBAP or fragments of LBAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

35 "Consensus sequence" refers to a nucleic acid sequence which has been resequenced to

resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of one or more Incyte Clones and, in some cases, one or more public domain ESTs, using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that, when made, least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
15	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
20	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
25	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
30	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function

WO 00/52161

PCT/US00/05153

of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "fragment" is a unique portion of LBAP or the polynucleotide encoding LBAP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:6-10 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:6-10, for example, as distinct from any other sequence in the same genome. A fragment of SEQ ID NO:6-10 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:6-10 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:6-10 and the region of SEQ ID NO:6-10 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-5 is encoded by a fragment of SEQ ID NO:6-10. A fragment of SEQ ID NO:1-5 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-5. For example, a fragment of SEQ ID NO:1-5 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-5. The precise length of a fragment of SEQ ID NO:1-5 and the region of SEQ ID NO:1-5 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization

WO 00/52161

PCT/US00/05153

assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequence pairs.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to

compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Reward for match: 1

5 *Penalty for mismatch: -2*

Open Gap: 5 and Extension Gap: 2 penalties

Gap x drop-off: 50

Expect: 10

Word Size: 11

10 *Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous
15 nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes
20 in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some
25 alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the hydrophobicity and acidity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e
30 sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

35 Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise

WO 00/52161

PCT/US00/05153

comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) with blastp set at default parameters. Such default parameters may be, for example:

Matrix: BLOSUM62

Open Gap: 11 and Extension Gap: 1 penalties

5 *Gap x drop-off: 50*

Expect: 10

Word Size: 3

Filter: on

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

The term “humanized antibody” refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about

5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_m and conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of LBAP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of LBAP which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" and "array element" in a microarray context, refer to hybridizable polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of LBAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of LBAP.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Probe" refers to nucleic acid sequences encoding LBAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes.

"Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold

transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

5 An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

10 The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding LBAP, or fragments thereof, or LBAP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

15 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

20 The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

25 A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

30 "Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term

35

WO 00/52161

PCT/US00/05153

"transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, and plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of

WO 00/52161

PCT/US00/05153

the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

5 THE INVENTION

The invention is based on the discovery of new human leukocyte- and blood-associated proteins (LBAP), the polynucleotides encoding LBAP, and the use of these compositions for the diagnosis, treatment, or prevention of autoimmune/inflammatory disorders and cell proliferative disorders including cancer.

10 Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding LBAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each LBAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA
15 libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The Incyte clones in column 5 were used to assemble the consensus nucleotide sequence of each LBAP and are useful as fragments in hybridization technologies.

The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each
20 polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and
25 protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding LBAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists tissue categories which express LBAP as a fraction of total tissues expressing LBAP. Column 3 lists diseases, disorders, or conditions associated with those
30 tissues expressing LBAP as a fraction of total tissues expressing LBAP. Column 4 lists the vectors used to subclone each cDNA library. Of particular note is the expression of SEQ ID NO:10 in a primary osteogenic sarcoma cell line.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding LBAP were isolated. Column 1 references the nucleotide SEQ
35 ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3

WO 00/52161

PCT/US00/05153

shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The following fragments of the nucleotide sequences encoding LBAP are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:6-10 and to distinguish between SEQ ID NO:6-10 and related polynucleotide sequences. The useful fragments include the fragment of SEQ ID NO:6 from about nucleotide 865 to about nucleotide 909; the fragment of SEQ ID NO:7 from about nucleotide 433 to about nucleotide 474; the fragment of SEQ ID NO:8 from about nucleotide 182 to about nucleotide 223; the fragment of SEQ ID NO:9 from about nucleotide 408 to about nucleotide 452; and the fragment of SEQ ID NO:10 from about nucleotide 356 to about nucleotide 418. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides.

The invention also encompasses LBAP variants. A preferred LBAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the LBAP amino acid sequence, and which contains at least one functional or structural characteristic of LBAP.

The invention also encompasses polynucleotides which encode LBAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:6-10, which encodes LBAP. The polynucleotide sequences of SEQ ID NO:6-10, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The invention also encompasses a variant of a polynucleotide sequence encoding LBAP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding LBAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:6-10 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:6-10. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of LBAP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding LBAP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the

Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding LBAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer

WO 00/52161

PCT/US00/05153

controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode LBAP may be cloned in recombinant DNA molecules that direct expression of LBAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express LBAP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter LBAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of LBAP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding LBAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.)

Alternatively, LBAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g.,

Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of LBAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

5 The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY.)

10 In order to express a biologically active LBAP, the nucleotide sequences encoding LBAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences
15 encoding LBAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding LBAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding LBAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals
20 may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

25 Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding LBAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

35 A variety of expression vector/host systems may be utilized to contain and express sequences encoding LBAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with

yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., T1 or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

5 In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding LBAP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding LBAP can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding LBAP into the vector's multiple
10 cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for *in vitro* transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of LBAP are needed, e.g. for the production of
15 antibodies, vectors which direct high level expression of LBAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of LBAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such
20 vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, *supra*; Bitter, G.A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C.A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of LBAP. Transcription of sequences
25 encoding LBAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.)
30 These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding LBAP may be ligated into
35 an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader

sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses LBAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of LBAP in cell lines is preferred. For example, sequences encoding LBAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk⁻* and *apr⁻* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is

also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding LBAP is inserted within a marker gene sequence, transformed cells containing sequences encoding LBAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding LBAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding LBAP and that express LBAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of LBAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on LBAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding LBAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding LBAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding LBAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein

precursor, for example, ³⁵S-methionine.

Fragments of LBAP may be produced not only by recombinant means, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A peptide synthesizer (Perkin-Elmer). Various fragments of LBAP may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of LBAP and leukocyte- and blood-associated proteins. In addition, the expression of LBAP is closely associated with cell proliferation, cancer, and inflammation. Therefore, LBAP appears to play a role in autoimmune/inflammatory disorders and cell proliferative disorders including cancer. In the treatment of disorders associated with increased LBAP expression or activity, it is desirable to decrease the expression or activity of LBAP. In the treatment of disorders associated with decreased LBAP expression or activity, it is desirable to increase the expression or activity of LBAP.

Therefore, in one embodiment, LBAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of LBAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and a cancer including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's

syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma.

5 In another embodiment, a vector capable of expressing LBAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of LBAP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified LBAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat
10 or prevent a disorder associated with decreased expression or activity of LBAP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of LBAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of LBAP including, but not limited to, those listed above.

15 In a further embodiment, an antagonist of LBAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of LBAP. Examples of such disorders include, but are not limited to, those autoimmune/inflammatory disorders and cell proliferative disorders, including cancer, described above. In one aspect, an antibody which specifically binds LBAP may be used directly as an antagonist or indirectly as a targeting or delivery
20 mechanism for bringing a pharmaceutical agent to cells or tissues which express LBAP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding LBAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of LBAP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary
25 sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic
30 efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of LBAP may be produced using methods which are generally known in the art. In particular, purified LBAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind LBAP. Antibodies to LBAP may also be generated using methods that are well known in the art. Such antibodies may include, but are not
35 limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and

fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with LBAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to LBAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of LBAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to LBAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce LBAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for LBAP may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between LBAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering LBAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods, such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for LBAP. Affinity is expressed as an association constant, K_a, which is defined as the molar concentration of LBAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple LBAP epitopes, represents the average affinity, or avidity, of the antibodies for LBAP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular LBAP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10⁹ to 10¹² L/mole are preferred for use in immunoassays in which the LBAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10⁶ to 10⁷ L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of LBAP, preferably in active form, from the antibody (Catty, D. (1988) *Antibodies, Volume I: A Practical Approach*, IRL Press, Washington, DC; Liddell, J.E. and Cryer, A. (1991) *A Practical Guide to Monoclonal Antibodies*, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of LBAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, *supra*, and Coligan et al. *supra*.)

In another embodiment of the invention, the polynucleotides encoding LBAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding LBAP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding LBAP. Thus, complementary molecules or fragments may be used to modulate LBAP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding LBAP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding LBAP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding LBAP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding LBAP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding LBAP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may be employed. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example,

WO 00/52161

PCT/US00/05153

engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding LBAP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding LBAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use *in vivo*, *in vitro*, and *ex vivo*. For *ex vivo* therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a pharmaceutical

WO 00/52161

PCT/US00/05153

or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of LBAP, antibodies to LBAP, and mimetics, agonists, antagonists, or inhibitors of LBAP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of

gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of LBAP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of

administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example LBAP or fragments thereof, antibodies of LBAP, and agonists, antagonists or inhibitors of LBAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1 μ g to 100,000 μ g, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind LBAP may be used for the diagnosis of disorders characterized by expression of LBAP, or in assays to monitor patients being treated with LBAP or agonists, antagonists, or inhibitors of LBAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for LBAP include methods which utilize the antibody and a label to detect LBAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and

may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring LBAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of LBAP expression. Normal or standard values for LBAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to LBAP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of LBAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values.

Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding LBAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of LBAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of LBAP, and to monitor regulation of LBAP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding LBAP or closely related molecules may be used to identify nucleic acid sequences which encode LBAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding LBAP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the LBAP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:6-10 or from genomic sequences including promoters, enhancers, and introns of the LBAP gene.

Means for producing specific hybridization probes for DNAs encoding LBAP include the cloning of polynucleotide sequences encoding LBAP or LBAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding LBAP may be used for the diagnosis of disorders

associated with expression of LBAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and a cancer including

5 adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS),

10 Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis,

15 erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura,

20 ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma. The polynucleotide sequences encoding LBAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect

25 altered LBAP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding LBAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding LBAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a

30 suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding LBAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to

monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of LBAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding LBAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding LBAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding LBAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding LBAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

Methods which may also be used to quantify the expression of LBAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

WO 00/52161

PCT/US00/05153

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding LBAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding LBAP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti,

R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

5 In another embodiment of the invention, LBAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between LBAP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds 10 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with LBAP, or fragments thereof, and washed. Bound LBAP is then detected by methods well known in the art. Purified LBAP can also be coated directly onto plates for use in the aforementioned drug screening techniques.

15 Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding LBAP specifically compete with a test compound for binding LBAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more 20 antigenic determinants with LBAP.

In additional embodiments, the nucleotide sequences which encode LBAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

25 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in 30 particular U.S. Ser. No.60/122,080, are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some 35 tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized

and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

5 Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A⁺) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA
10 purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, *supra*, units
15 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs
20 were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPOrt1 plasmid (Life Technologies), pcDNA2.1 plasmid (Invitrogen, Carlsbad CA), or pINCY plasmid (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies.

25 II. Isolation of cDNA Clones

Plasmids were recovered from host cells by *in vivo* excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8
30 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal
35 cycling steps were carried out in a single reaction mixture. Samples were processed and stored in

384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

5 cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing
10 kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading
15 frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the
20 art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other
25 parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence
30 alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried
35 against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate,

WO 00/52161

PCT/US00/05153

and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA.

5 The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene
10 families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:6-10. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

15 IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

20 Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$25 \quad \frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules
30 are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding LBAP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic,
35 developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous,

reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in

5 Table 3.

V. Extension of LBAP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:6-10 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other
10 primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

15 Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$,
20 and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2:
25 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar,
30 Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending the sequence.

35 The extended nucleotides were desalted and concentrated, transferred to 384-well plates,

digested with CviII cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones
5 were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

10 The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA
15 recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:6-10 are used to obtain 5' regulatory
20 sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:6-10 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base
25 pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a
30 SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon
35 membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16

hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

5 **VII. Microarrays**

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, *supra*.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand
10 or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

15 Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an
20 appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

25 **VIII. Complementary Polynucleotides**

Sequences complementary to the LBAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring LBAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are
30 designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of LBAP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the LBAP-encoding transcript.

IX. Expression of LBAP

Expression and purification of LBAP is achieved using bacterial or virus-based expression systems. For expression of LBAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express LBAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of LBAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding LBAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, LBAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from LBAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified LBAP obtained by these methods can be used directly in the following activity assay.

X. Demonstration of LBAP Activity

An assay for LBAP activity measures the expression of LBAP on the cell surface. cDNA encoding LBAP is transfected into a mammalian (non-human) cell line. Cell surface proteins are labeled with biotin as described in de la Fuente, M.A. et al. (1997, Blood 90:2398-2405). Immunoprecipitations are performed using LBAP-specific antibodies, and immunoprecipitated

samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of LBAP expressed on the cell surface.

XI. Functional Assays

5 LBAP function is assessed by expressing the sequences encoding LBAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT plasmid (Life Technologies) and pCR3.1 plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into
10 a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP;
15 Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide;
20 changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are
25 discussed in Ormerod, M.G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of LBAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding LBAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected
30 cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding LBAP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XII. Production of LBAP Specific Antibodies

LBAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the LBAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-LBAP activity by, for example, binding the peptide or LBAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIII. Purification of Naturally Occurring LBAP Using Specific Antibodies

Naturally occurring or recombinant LBAP is substantially purified by immunoaffinity chromatography using antibodies specific for LBAP. An immunoaffinity column is constructed by covalently coupling anti-LBAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing LBAP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of LBAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/LBAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and LBAP is collected.

XIV. Identification of Molecules Which Interact with LBAP

LBAP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled LBAP, washed, and any wells with labeled LBAP complex are assayed. Data obtained using different concentrations of LBAP are used to calculate values for the number, affinity, and association of LBAP with the candidate molecules.

Alternatively, molecules interacting with LBAP are analyzed using the yeast two-hybrid

WO 00/52161

PCT/US00/05153

system as described in Fields, S. and O. Song (1989, Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table I

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	6	1450888	PENITUT01	1450888H1 (PENITUT01), 2124875H1 (BRSTNOT07), 2899344F6 (DRGCNOT01), 3150886R6 (ADREN04), 3150886T6 (ADREN04), 3675980F6 (PLACNOT07), 3687969T6 (HEANOT01), 4872387H1 (COLDNOT01), SBAA01346F1
2	7	1929823	COLNTUT03	1341151F6 (COLNTUT03), 1794066H1 (PROSTUT05), 1929823H1 (COLNTUT03), 3240284H1 (COLAUCT01), 3274531H1 (PROSEPT06), SCCA01243V1, SCCA02331V1, SCCA04417V1, SCCA04745V1, SCCA04854V1
3	8	2050566	LIVRFET02	1952854T6 (PITUNOT01), 2050566H1 (LIVRFET02)
4	9	2479425	SMCANOT01	1379146F1 (LUNGNOT10), 1440815R1 (THYRNOT03), 1593947F6 (BRAINOT14), 2212142F6 (SINTFET03), 2479425F7 (SMCANOT01), 2479425H1 (SMCANOT01), 2705028T6 (PONSAT01), 3831812H1 (PANCNOT17)
5	10	3073609	BONEUNT01	3073609F6 (BONEUNT01), 3073609H1 (BONEUNT01)

Table 2

SEQ ID No.	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences	Identification	Analytical Methods
1	256	T59 T131 S190 T196 S252	N104	Transmembrane domain: I164-V182 Signal peptide: M1-A23	CGM7 (antigenically related to CEA) (g3851200)	HMM BLAST SPScan
2	387	S101 S261 S379 S267 S376 Y163	N194	Transmembrane domains: L167-M189, M213-I237, N281-I299, V74-W94, I114-F134 Signal peptide: M1-A51	Lymphokine activated killer T cell associated protein LAK-4p (g2760121)	HMM BLAST SPScan
3	146	S52 T59 T94 T112 T17 T59 S75 T107 T124 S135	N23 N67	Signal peptide: M1-A20	HERV-E envelope glycoprotein (g2587024)	HMM BLAST
4	440	T2 S32 T42 T98 T19 T77 T215 T230 S251 S292 S353 S389 Y231	N154 N290	Transmembrane domain: P410-M434 Immunoglobulin domains: G6-A99, G146-A235, G282-P373	Leukocyte surface protein V7 (g1658310)	HMM BLAST PFAM
5	132	T124 S60 S123 Y128			Putative haemopoietic membrane protein (g3355655)	BLAST

Table 3

SEQ ID No:	Tissue Expression (Fraction of Total)	Disease or Condition (Fraction of Total)	Vector
6	Reproductive (0.417) Gastrointestinal (0.250) Developmental (0.083) Nervous (0.083) Endocrine (0.083) Urologic (0.083)	Cancer and Cell Proliferation (0.583) Inflammation (0.417)	pINCY
7	Reproductive (0.476) Gastrointestinal (0.381) Urologic (0.095)	Cancer and Cell Proliferation (0.762) Inflammation (0.238)	pINCY
8	Reproductive (0.600) Nervous (0.200) Endocrine (0.100) Gastrointestinal (0.100)	Cancer and Cell Proliferation (0.500) Inflammation (0.200)	pINCY
9	Nervous (0.406) Reproductive (0.188) Cardiovascular (0.156)	Cancer and Cell Proliferation (0.578) Inflammation (0.359) Neurological (0.078)	pINCY
10	Musculoskeletal (1.000)	Cancer and Cell Proliferation (1.000)	pINCY

Table 4

Nucleotide SEQ ID NO:	Library	Library Comment
6	PENITUT01	Library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-old Caucasian male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease.
7	COLNTUT03	Library was constructed using RNA isolated from colon tumor tissue obtained from the sigmoid colon of a 62-year-old Caucasian male during a sigmoidectomy and permanent colostomy. Pathology indicated invasive grade 2 adenocarcinoma. One lymph node contained metastasis with extranodal extension. Patient history included hyperlipidemia, cataract disorder, and dermatitis. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, breast cancer, and prostate cancer.
8	LIVRFET02	Library was constructed using RNA isolated from liver tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation. Family history included seven days of erythromycin treatment for bronchitis in the mother during the first trimester.
9	SMCANCT01	Library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male during a heart transplant.
10	BONEUNT01	Library was constructed using RNA isolated from Saos-2, a primary osteogenic sarcoma cell line (ATCC HTB-85) derived from an 11-year-old Caucasian female.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1 0E-8 or less Full Length sequences: Probability value= 1 0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, tfastx, tfastn, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1 06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1 0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits for PFAM hits, depending on individual protein families

Table 5 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Normalized quality score ≥ GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=3.5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

WO 00/52161

PCT/US00/05153

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-5,
 - b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-5,
 - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5, and
 - 10 d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-5.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-5.
- 15 3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide of claim 3 selected from the group consisting of SEQ ID NO:6-10.
- 20 5. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
6. A cell transformed with a recombinant polynucleotide of claim 5.
- 25 7. A transgenic organism comprising a recombinant polynucleotide of claim 5.
8. A method for producing a polypeptide of claim 1, the method comprising:
 - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide
 - 30 comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
 - b) recovering the polypeptide so expressed.
9. An isolated antibody which specifically binds to a polypeptide of claim 1.

10. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:6-10,
- b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:6-10,
- c) a polynucleotide sequence complementary to a),
- d) a polynucleotide sequence complementary to b), and
- e) an RNA equivalent of a)-d).

11. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 10.

12. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

- a) hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.


13. A method of claim 12, wherein the probe comprises at least 30 contiguous nucleotides.

14. A method of claim 12, wherein the probe comprises at least 60 contiguous nucleotides.

15. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

16. A method for treating a disease or condition associated with decreased expression of functional LBAP, comprising administering to a patient in need of such treatment the pharmaceutical composition of claim 15.

17. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:



- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

18. A pharmaceutical composition comprising an agonist compound identified by a method
5 of claim 17 and a pharmaceutically acceptable excipient.

19. A method for treating a disease or condition associated with decreased expression of
functional LBAP, comprising administering to a patient in need of such treatment a pharmaceutical
composition of claim 18.

10

20. A method for screening a compound for effectiveness as an antagonist of a polypeptide
of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

15

21. A pharmaceutical composition comprising an antagonist compound identified by a
method of claim 20 and a pharmaceutically acceptable excipient.

22. A method for treating a disease or condition associated with overexpression of functional
20 LBAP, comprising administering to a patient in need of such treatment a pharmaceutical composition
of claim 21.

23. A method for screening a compound for effectiveness in altering expression of a target
polynucleotide, wherein said target polynucleotide comprises a sequence of claim 4, the method
25 comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, and
- b) detecting altered expression of the target polynucleotide.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number
WO 00/52161 A3

(51) International Patent Classification⁷: C12N 15/12,
C07K 14/705, C12N 5/10, A01K 67/027, C12P 21/02,
C07K 16/28, C12Q 1/68, A61K 38/17, G01N 33/53

14244 Santiago Road, San Leandro, CA 94577 (US).
TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose,
CA 95118 (US). AZIMZAI, Valda [US/US]; 2045 Rock
Springs Drive, Hayward, CA 94545 (US).

(21) International Application Number: PCT/US00/05153

(22) International Filing Date: 29 February 2000 (29.02.2000)

(74) Agents: HAMLET-COX, Diana et al.; Incyte Pharma-
ceuticals, Inc., 3160 Porter Drive, Palo Alto, CA 94304
(US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/122,080 1 March 1999 (01.03.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:

US 60/122,080 (CIP)
Filed on 1 March 1999 (01.03.1999)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): INCYTE
PHARMACEUTICALS, INC. [US/US]; 3160 Porter
Drive, Palo Alto, CA 94304 (US).

Published:

— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): LAL, Preeti
[IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US).
YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale,
CA 94087 (US). HILLMAN, Jennifer, L. [US/US]; 230
Monroe Drive #12, Mountain View, CA 94040 (US). LU,
Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San
Jose, CA 95136 (US). BAUGHN, Mariah, R. [US/US];

(88) Date of publication of the international search report:
29 March 2001

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: LEUKOCYTE- AND BLOOD-ASSOCIATED PROTEINS

(57) Abstract: The invention provides human leukocyte- and blood-associated proteins (LBAP) and polynucleotides which identify and encode LBAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of LBAP.

WO 00/52161 A3



Docket No.: PF-0673 USN

DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

LEUKOCYTE AND BLOOD-ASSOCIATED PROTEINS

the specification of which:

/___/ is attached hereto.

/___/ was filed on _____ as application Serial No. _____ and if this box contains an X /___/, was amended on _____.

/X_/ was filed as Patent Cooperation Treaty international application No. PCT/US00/05153 on February 29, 2000, if this box contains an X /___/, was amended on under Patent Cooperation Treaty Article 19 on _____ 2001, and if this box contains an X /___/, was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

Docket No.: PF-0673 USN

Country	Number	Filing Date	Priority Claimed
_____	_____	_____	// Yes // No
_____	_____	_____	// Yes // No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

Application	Status (Pending,
Serial No.	Abandoned, Patented)
60/122,080	Expired

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application	Status (Pending,
Serial No.	Abandoned, Patented)
_____	_____

I hereby appoint the following:

Lucy J. Billings	Reg. No. <u>36,749</u>
Michael C. Cerrone	Reg. No. <u>39,132</u>
Diana Hamlet-Cox	Reg. No. <u>33,302</u>
Richard C. Ekstrom	Reg. No. <u>37,027</u>
Barrie D. Greene	Reg. No. <u>46,740</u>
Matthew R. Kaser	Reg. No. <u>44,817</u>
Lynn E. Murry	Reg. No. <u>42,918</u>
Shirley A. Recipon	Reg. No. <u>47,016</u>
Susan K. Sather	Reg. No. <u>44,316</u>
Michelle M. Stempien	Reg. No. <u>41,327</u>
David G. Streeter	Reg. No. <u>43,168</u>
Stephen Todd	Reg. No. <u>47,139</u>
P. Ben Wang	Reg. No. <u>41,420</u>

13

respectively and individually, as my patent attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

Docket No.: PF-0673 USN

**LEGAL DEPARTMENT
INCYTE GENOMICS, INC.
3160 PORTER DRIVE, PALO ALTO, CA 94304**

TEL: 650-855-0555 FAX: 650-849-8886 or 650-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

First Joint Inventor:

1-80

Full name:

Preeti Lal

Signature:

Preeti Lal

Date:

September 10, 2001

Citizenship:

India

Residence:

Santa Clara, California CA

P.O. Address:

P.O. Box 5142
Santa Clara, California 95056

Second Joint Inventor:

200

Full name:

Henry Yue

Signature:

Henry Geo

Date:

September 64, 2001

Citizenship:

United States

Residence:


Sunnyvale, California CA

P.O. Address:


826 Lois Avenue
Sunnyvale, California 94087

Docket No.: PF-0673 USN


Third Joint Inventor:

3-00
Full name: Jennifer L. Hillman
Signature: 
Date: September 21, 2001
Citizenship: United States
Residence: Mountain View, California CA
P.O. Address: 230 Monroe Drive, #17
Mountain View, California 94040

Fourth Joint Inventor:


4-00
Full name: Dyung Aina M. Lu
Signature: 
Date: September 7, 2001
Citizenship: United States
Residence: San Jose, California CA
P.O. Address: 233 Coy Drive
San Jose, California 95123

Fifth Joint Inventor:


5-00
Full name: Mariah R. Baughn
Signature: 
Date: September 5, 2001
Citizenship: United States
Residence: San Leandro, California CA
P.O. Address: 14244 Santiago Road
San Leandro, California 94577

Docket No.: PF-0673 USN

Sixth Joint Inventor:

6-00
 Full name: Y. Tom Tang
 Signature: 
 Date: Sept 10, 2001
 Citizenship: United States
 Residence: San Jose, California CA
 P.O. Address: 4230 Ranwick Court
San Jose, California 95118

Seventh Joint Inventor:

7-00
 Full name: Yalda Azimzai
 Signature: 
 Date: September 13, 2001
 Citizenship: United States
 Residence: Castro Valley, California CA
 P.O. Address: 5518 Boulder Canyon Drive
Castro Valley, California 94552

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

LAL, Preeti

YUE, Henry

HILLMAN, Jennifer L.

LU, Dyung Aina M.

BAUGHN, Mariah R.

TANG, Y. Tom

AZIMZAI, Yalda

<120> LEUKOCYTE- AND BLOOD-ASSOCIATED PROTEINS

<130> PF-0673 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/122,080

<151> 1999-03-01

<160> 10

<170> PERL Program

<210> 1

<211> 256

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1450888CD1

<400> 1

Met	Glu	Ile	Pro	Met	Gly	Thr	Gln	Gly	Cys	Phe	Ser	Lys	Ser	Leu	1	5	10	15
Leu	Leu	Ser	Ala	Ser	Ile	Leu	Val	Leu	Trp	Met	Leu	Gln	Gly	Ser	20	25	30	35
Gln	Ala	Ala	Leu	Tyr	Ile	Gln	Lys	Ile	Pro	Glu	Gln	Pro	Gln	Lys	40	45	50	55
Asn	Gln	Asp	Leu	Leu	Leu	Ser	Val	Gln	Gly	Val	Pro	Asp	Thr	Phe	60	65	70	75
Gln	Asp	Phe	Asn	Trp	Tyr	Leu	Gly	Glu	Glu	Thr	Tyr	Gly	Gly	Thr	80	85	90	95
Arg	Leu	Phe	Thr	Tyr	Ile	Pro	Gly	Ile	Gln	Arg	Pro	Gln	Arg	Asp	100	105	110	115
Gly	Ser	Ala	Met	Gly	Gln	Arg	Asp	Ile	Val	Gly	Phe	Pro	Asn	Gly	120	125	130	135
Ser	Met	Leu	Leu	Arg	Arg	Ala	Gln	Pro	Thr	Asp	Ser	Gly	Thr	Tyr	140	145	150	155
Gln	Val	Ala	Ile	Thr	Ile	Asn	Ser	Glu	Trp	Thr	Met	Lys	Ala	Lys	160	165	170	175
Thr	Glu	Val	Gln	Val	Ala	Glu	Lys	Asn	Lys	Glu	Leu	Pro	Ser	Thr	180	185	190	195
His	Leu	Pro	Thr	Asn	Ala	Gly	Ile	Leu	Ala	Ala	Thr	Ile	Ile	Gly	200	205	210	215
Ser	Leu	Ala	Ala	Gly	Ala	Leu	Leu	Ile	Ser	Cys	Ile	Ala	Tyr	Leu	220	225	230	235
Leu	Val	Thr	Arg	Asn	Trp	Arg	Gly	Gln	Ser	His	Arg	Met	Ala	Thr	240	245	250	255
Thr	Glu	Lys	Pro	Glu	Leu	Gly	Pro	Ala	His	Asp	Ala	Gly	Asp	Asn	260	265	270	275
Asn	Ile	Tyr	Glu	Val	Met	Pro	Ser	Pro	Val	Leu	Leu	Val	Ser	Pro	280	285	290	295
Ile	Ser	Asp	Thr	Arg	Ser	Ile	Asn	Pro	Ala	Arg	Pro	Leu	Pro	Thr	300	305	310	315

WO 00/52161

PCT/US00/05153

Pro Pro His Leu Gln Ala Glu Gln Arg Thr Thr Ser Thr Arg Thr
245 250 255
Cys

<210> 2
<211> 387
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1929823CD1

<400> 2
Met Val Ala Trp Val Val Ser Thr Gly Val Ala Ile Ala Cys Cys
1 5 10 15
Ala Ala Val Tyr Tyr Leu Ala Glu Tyr Asn Leu Glu Phe Leu Lys
20 25 30
Thr His Ser Asn Pro Gly Ala Val Leu Leu Leu Pro Phe Val Val
35 40 45
Ser Cys Ile Asn Leu Ala Val Pro Cys Ile Tyr Ser Met Phe Arg
50 55 60
Leu Val Glu Arg Tyr Glu Met Pro Arg His Glu Val Tyr Val Leu
65 70 75
Leu Ile Arg Asn Ile Phe Leu Lys Ile Ser Ile Ile Gly Ile Leu
80 85 90
Cys Tyr Tyr Trp Leu Asn Thr Val Ala Leu Ser Gly Glu Glu Cys
95 100 105
Trp Glu Thr Leu Ile Gly Gln Asp Ile Tyr Arg Leu Leu Leu Met
110 115 120
Asp Phe Val Phe Ser Leu Val Asn Ser Phe Leu Gly Glu Phe Leu
125 130 135
Arg Arg Ile Ile Gly Met Gln Leu Ile Thr Ser Leu Gly Leu Gln
140 145 150
Glu Phe Asp Ile Ala Arg Asn Val Leu Glu Leu Ile Tyr Ala Gln
155 160 165
Thr Leu Val Trp Ile Gly Ile Phe Phe Cys Pro Leu Leu Pro Phe
170 175 180
Ile Gln Met Ile Met Leu Phe Ile Met Phe Tyr Ser Lys Asn Ile
185 190 195
Ser Leu Met Met Asn Phe Gln Pro Pro Ser Lys Ala Trp Arg Ala
200 205 210
Ser Gln Met Met Thr Phe Phe Ile Phe Leu Leu Phe Phe Pro Ser
215 220 225
Phe Thr Gly Val Leu Cys Thr Leu Ala Ile Thr Ile Trp Arg Leu
230 235 240
Lys Pro Ser Ala Asp Cys Gly Pro Phe Arg Gly Leu Pro Leu Phe
245 250 255
Ile His Ser Ile Tyr Ser Trp Ile Asp Thr Leu Ser Thr Arg Pro
260 265 270
Gly Tyr Leu Trp Val Val Trp Ile Tyr Arg Asn Leu Ile Gly Ser
275 280 285
Val His Phe Phe Phe Ile Leu Thr Leu Ile Val Leu Ile Ile Thr
290 295 300
Tyr Leu Tyr Trp Gln Ile Thr Glu Gly Arg Lys Ile Met Ile Arg
305 310 315
Leu Leu His Glu Gln Ile Ile Asn Glu Gly Lys Asp Lys Met Phe
320 325 330
Leu Ile Glu Lys Leu Ile Lys Leu Gln Asp Met Glu Lys Lys Ala
335 340 345
Asn Pro Ser Ser Leu Val Leu Glu Arg Arg Glu Val Glu Gln Gln
350 355 360
Gly Phe Leu His Leu Gly Glu His Asp Gly Ser Leu Asp Leu Arg
365 370 375
Ser Arg Arg Ser Val Gln Glu Gly Asn Pro Arg Ala
380 385

WO 00/52161

PCT/US00/05153

<210> 6
 <211> 2348
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1450888CB1

<400> 6
 accaatccaa aaactacaaa atattcttgc aattataggt gacatattta aatggtaaga 60
 caaccaatgt tcatgaatgg aaagacagag caagaccctg tctcaagaaa aaaaaaaaaa 120
 aaaaaaaaaa aaaaaaaaaa aggctgagcc accgcaccca gcttgcctca gaggcttcaa 180
 gtgagtcagc cacaggtgaa atcccacctc tgtctatttg cagacttgcc tcttttcctg 240
 ggctctgtgt tccacatctg tgcaatggga acagttattt atgggtggctg ctgaatgagg 300
 cagtgtgtgt ttgaacaaac ccagggggaat tgttcaaaca gaggctgtta tgactattgc 360
 tacagtgact gctgtttag tagcgtgag tgagaaaaag aggttgaaga gggtcagggg 420
 aggagtcttg ggaagtccc cagtcaccct gaaaaactgg ttcaacctct gctgtgctc 480
 ccatcccagg gagtataggt ggagcctcca gagcccatgg acagggcatg ctggggctgg 540
 gccagcccca gcggtgtctc taaggcaccc ctgggatccc cactgagctg gcctacttca 600
 gcacagccag gccccacccct ctggcccccct tagtgctccag ctctgggccc cttggcattt 660
 ccacaagacg ccaagatgga gattcccctg gggaccagg gctgcttctc aaagagctac 720
 ctgctctcag cctcaatcct ggctctctgg atgctccaag gctcccaggc agctctctac 780
 atccagaaga tccagagca gcctcaaaag aaccaggacc ttctcctgtc agtccagggt 840
 gtcccagaca ccttccagga cttcaactgg tacctggggg aggagacgta cggaggcacg 900
 aggtatttta cctacatccc tgggatacaa cggcctcaga gggatggcag tgccatggga 960
 cagcgagaca tctgtgggctt cccaatgggt tccatgtctg tgcgcgcgcg ccagcctaca 1020
 gacagtggca cctaccaagt agccattacc atcaactctg aatggactat gaaggccaag 1080
 actgaggtcc aggtagctga aaagaataag gagctgcccc gtacacacct gccaccaaac 1140
 gctgggacac tggcgggccac catcattgga tctcttctgt cccggggccc tctcatcagc 1200
 tgcattgcct atctcctggt gacaaggaac tggaggggcc agagccacag gatggcgacc 1260
 acagagaagc cagaattggg cctgtctcat gatgctgggt acaacaacat ctatgaagtg 1320
 atgcccctct cagtctcctt ggtgtcccc atcagtgaca caaggtccat aaaccagacc 1380
 cggcccccct ccacaccccc acacctgcag gcggagcaga gaaccaccag taccaggacc 1440
 tgcataaacc cgaccctgcc cctaactgcc agctgggtgc aacttctga tgggtcctgg 1500
 gccaggccag ccaggggaga gacaaggccc cagccctcct ctgggagcct cacacctgag 1560
 accagcagga caaggccatt gggggctgtg gggccgatga ggtggactca gccaaagact 1620
 cagcagcaca tggggcaggt gtccctggcag ggggacagga gactgtaaca ggcccaggtc 1680
 cttgtgcagc ccttgaatgc acgcccgcct tgggtctgtt ccttcaagca agctggcctg 1740
 ggccatgtgc ctgtgaaagg caggtctctg cccctttcca tgccaaagtc cccaagatc 1800
 tggatatctg gggacaagat ggtggcctca ggccctgcct ccaggcagtt ggctgggctc 1860
 ccaactgtct gtccctcaatg cctaccccc actccactag tgaccctcag agtcttcttc 1920
 ccttaggaca aggcagacac ccaccatgc aggcctcagg tggcagagag gccagcctc 1980
 acaggcctgt ggccccacac accagtccca gcaagggtgac cacggctgct ggacccttc 2040
 cctgttcagg caggcccagc cctctcaga acctgctgcc agctgctggt cttggcccc 2100
 accctgaatc ttactgagtc cctctgggca gcagctccct tctccacccc accccagcac 2160
 ccgtcccaaa tgtggcctca gcttgcctc cccttcccca aactatgcat tcatagaca 2220
 ataaatgagc ctttgcgtgt tgccagacc agttctaggg tcttgacgac ctggtagaaa 2280
 gcaaaacaaa aactcccgct ttcccagagg gtcacttggc aggggaaaga atcaggaaat 2340
 aaacaaat 2348

<210> 7
 <211> 2243
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1929823CB1

<400> 7
 ctaaaacaga agaattcttag cactgagata agggagaacc tgtcagagct ccgtcaggag 60
 aattccaagt tgacgttcaa tcagctgctg acccgcttct ctgcctacat ggtagcctgg 120
 gttgtctcta caggagtggc catagcctgc tgtgcagccg tttattacct ggctgagtac 180
 aacttagagt tctgaagac acacagtaac cctggggcgg tgctgttact gcctttcgtt 240
 gtgtcctgca ttaattctggc cgtgccatgc atctactcca tgttcaggct tgtggagagg 300

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

LAL, Preeti

YUE, Henry

HILLMAN, Jennifer L.

LU, Dyung Aina M.

BAUGHN, Mariah R.

TANG, Y. Tom

AZIMZAI, Yalda

<120> LEUKOCYTE- AND BLOOD-ASSOCIATED PROTEINS

<130> PF-0673 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/122,080

<151> 1999-03-01

<160> 10

<170> PERL Program

<210> 1

<211> 256

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 1450888CD1

<400> 1

Met	Glu	Ile	Pro	Met	Gly	Thr	Gln	Gly	Cys	Phe	Ser	Lys	Ser	Leu
1				5					10					15
Leu	Leu	Ser	Ala	Ser	Ile	Leu	Val	Leu	Trp	Met	Leu	Gln	Gly	Ser
				20					25					30
Gln	Ala	Ala	Leu	Tyr	Ile	Gln	Lys	Ile	Pro	Glu	Gln	Pro	Gln	Lys
				35					40					45
Asn	Gln	Asp	Leu	Leu	Leu	Ser	Val	Gln	Gly	Val	Pro	Asp	Thr	Phe
				50					55					60
Gln	Asp	Phe	Asn	Trp	Tyr	Leu	Gly	Glu	Glu	Thr	Tyr	Gly	Gly	Thr
				65					70					75
Arg	Leu	Phe	Thr	Tyr	Ile	Pro	Gly	Ile	Gln	Arg	Pro	Gln	Arg	Asp
				80					85					90
Gly	Ser	Ala	Met	Gly	Gln	Arg	Asp	Ile	Val	Gly	Phe	Pro	Asn	Gly
				95					100					105
Ser	Met	Leu	Leu	Arg	Arg	Ala	Gln	Pro	Thr	Asp	Ser	Gly	Thr	Tyr
				110					115					120
Gln	Val	Ala	Ile	Thr	Ile	Asn	Ser	Glu	Trp	Thr	Met	Lys	Ala	Lys
				125					130					135
Thr	Glu	Val	Gln	Val	Ala	Glu	Lys	Asn	Lys	Glu	Leu	Pro	Ser	Thr
				140					145					150
His	Leu	Pro	Thr	Asn	Ala	Gly	Ile	Leu	Ala	Ala	Thr	Ile	Ile	Gly
				155					160					165
Ser	Leu	Ala	Ala	Gly	Ala	Leu	Leu	Ile	Ser	Cys	Ile	Ala	Tyr	Leu
				170					175					180
Leu	Val	Thr	Arg	Asn	Trp	Arg	Gly	Gln	Ser	His	Arg	Met	Ala	Thr
				185					190					195
Thr	Glu	Lys	Pro	Glu	Leu	Gly	Pro	Ala	His	Asp	Ala	Gly	Asp	Asn
				200					205					210
Asn	Ile	Tyr	Glu	Val	Met	Pro	Ser	Pro	Val	Leu	Leu	Val	Ser	Pro
				215					220					225
Ile	Ser	Asp	Thr	Arg	Ser	Ile	Asn	Pro	Ala	Arg	Pro	Leu	Pro	Thr
				230					235					240

WO 00/52161

PCT/US00/05153

Pro Pro His Leu Gln Ala Glu Gln Arg Thr Thr Ser Thr Arg Thr
 245 250 255
 Cys

<210> 2
 <211> 387
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 1929823CD1

<400> 2
 Met Val Ala Trp Val Val Ser Thr Gly Val Ala Ile Ala Cys Cys
 1 5 10 15
 Ala Ala Val Tyr Tyr Leu Ala Glu Tyr Asn Leu Glu Phe Leu Lys
 20 25 30
 Thr His Ser Asn Pro Gly Ala Val Leu Leu Leu Pro Phe Val Val
 35 40 45
 Ser Cys Ile Asn Leu Ala Val Pro Cys Ile Tyr Ser Met Phe Arg
 50 55 60
 Leu Val Glu Arg Tyr Glu Met Pro Arg His Glu Val Tyr Val Leu
 65 70 75
 Leu Ile Arg Asn Ile Phe Leu Lys Ile Ser Ile Ile Gly Ile Leu
 80 85 90
 Cys Tyr Tyr Trp Leu Asn Thr Val Ala Leu Ser Gly Glu Glu Cys
 95 100 105
 Trp Glu Thr Leu Ile Gly Gln Asp Ile Tyr Arg Leu Leu Leu Met
 110 115 120
 Asp Phe Val Phe Ser Leu Val Asn Ser Phe Leu Gly Glu Phe Leu
 125 130 135
 Arg Arg Ile Ile Gly Met Gln Leu Ile Thr Ser Leu Gly Leu Gln
 140 145 150
 Glu Phe Asp Ile Ala Arg Asn Val Leu Glu Leu Ile Tyr Ala Gln
 155 160 165
 Thr Leu Val Trp Ile Gly Ile Phe Phe Cys Pro Leu Leu Pro Phe
 170 175 180
 Ile Gln Met Ile Met Leu Phe Ile Met Phe Tyr Ser Lys Asn Ile
 185 190 195
 Ser Leu Met Met Asn Phe Gln Pro Pro Ser Lys Ala Trp Arg Ala
 200 205 210
 Ser Gln Met Met Thr Phe Phe Ile Phe Leu Leu Phe Phe Pro Ser
 215 220 225
 Phe Thr Gly Val Leu Cys Thr Leu Ala Ile Thr Ile Trp Arg Leu
 230 235 240
 Lys Pro Ser Ala Asp Cys Gly Pro Phe Arg Gly Leu Pro Leu Phe
 245 250 255
 Ile His Ser Ile Tyr Ser Trp Ile Asp Thr Leu Ser Thr Arg Pro
 260 265 270
 Gly Tyr Leu Trp Val Val Trp Ile Tyr Arg Asn Leu Ile Gly Ser
 275 280 285
 Val His Phe Phe Phe Ile Leu Thr Leu Ile Val Leu Ile Ile Thr
 290 295 300
 Tyr Leu Tyr Trp Gln Ile Thr Glu Gly Arg Lys Ile Met Ile Arg
 305 310 315
 Leu Leu His Glu Gln Ile Ile Asn Glu Gly Lys Asp Lys Met Phe
 320 325 330
 Leu Ile Glu Lys Leu Ile Lys Leu Gln Asp Met Glu Lys Lys Ala
 335 340 345
 Asn Pro Ser Ser Leu Val Leu Glu Arg Arg Glu Val Glu Gln Gln
 350 355 360
 Gly Phe Leu His Leu Gly Glu His Asp Gly Ser Leu Asp Leu Arg
 365 370 375
 Ser Arg Arg Ser Val Gln Glu Gly Asn Pro Arg Ala
 380 385

WO 00/52161

PCT/US00/05153

<210> 3
<211> 146
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2050566CD1

<400> 3
Met Arg Lys Leu Ile Val Arg Phe Ile Phe Leu Lys Phe Trp Thr
1 5 10 15
Tyr Thr Val Arg Ala Ser Thr Asn Leu Thr Gln Asn Gly Asp Cys
20 25 30
Ser Gln Cys Ile Tyr Gln Val Thr Glu Val Gly Gln Gln Ile Lys
35 40 45
Thr Ile Phe Leu Phe Tyr Ser Tyr Tyr Glu Cys Met Glu Thr Leu
50 55 60
Lys Glu Thr Cys Leu Tyr Asn Ala Thr Gln Tyr Lys Val Cys Ser
65 70 75
Pro Arg Asn Asp Arg Pro Asp Ala Cys Tyr Asn Pro Ser Glu Pro
80 85 90
Ala Ala Thr Thr Val Phe Glu Ile Arg Thr Gly Leu Leu Leu Gly
95 100 105
Asp Thr Ser Lys Ile Ile Thr Arg Thr Glu Glu Lys Glu Ile Pro
110 115 120
Lys Gln Ile Thr Leu Arg Phe Asp Ala Cys Ala Ala Ile Asn Ser
125 130 135
Lys Lys Leu Glu Ile Gly Cys Gly Ser Leu Asn
140 145

<210> 4
<211> 440
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2479425CD1

<400> 4
Met Thr Val His Glu Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala
1 5 10 15
Arg Thr Ser Thr Gln Lys His Thr His Leu Ala Val Ser Phe Gly
20 25 30
Arg Ser Val Pro Glu Ala Pro Val Gly Arg Ser Thr Leu Gln Glu
35 40 45
Val Val Gly Ile Arg Ser Asp Leu Ala Val Glu Ala Gly Ala Pro
50 55 60
Tyr Ala Glu Arg Arg Ala Ala Gly Glu Leu Arg Leu Gly Lys Glu
65 70 75
Gly Thr Asp Arg Tyr Arg Met Val Val Gly Gly Ala Gln Ala Gly
80 85 90
Asp Ala Gly Thr Tyr His Cys Thr Ala Ala Glu Trp Ile Gln Asp
95 100 105
Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu Lys Arg Ala Val Leu
110 115 120
Ala His Val Asp Val Gln Thr Leu Ser Ser Gln Leu Ala Val Thr
125 130 135
Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu Pro Leu Glu
140 145 150
Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly Arg His
155 160 165
Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly Ala Pro
170 175 180

WO 00/52161

PCT/US00/05153

<210> 6
<211> 2348
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1450888CB1

<400> 6
accaatccaa aaactacaaa atattcttgc aattataggt gacatattta aatggtaaga 60
caaccaatgt tcatgaatgg aaagacagag caagaccctg tctcaagaaa aaaaaaaaaa 120
aaaaaaaaaa aaaaaaaaaa aggctgagcc accgcaccca gcctgcctca gagccttcaa 180
gtgagtcagc cacaggtgaa atcccacctc tgtctattgg cagacttgcc tcttttccctg 240
ggcctctgtt tccacatctg tgcaatggga acagtatttt atgggtggctg ctgaatgagg 300
cagtgtgtgt ttgaacaaac ccaggggaat tgttcaaaca gaggtgtgta tgactattgc 360
tacagtgact gctgtttagt tcacgctgag tgagaaaaag aggttgaaga gggtcagggg 420
aggagctctg ggaagtccc cagtcaccct gaaaaactgg ttcaacctct gtctgtgctc 480
ccatcccagg gagtataggt ggagcctcca gagcccattg acagggcatg ctggggctgg 540
gccagcccca gcggtgtctc taaggcacc ctagggatccc cactgagctg gcctacttca 600
gacagccagg gccacccct ctggccccc tagtgtccag ctctgtggcc cttggcattt 660
ccacaagacg ccaagatgga gattcccatt gggaccacag gctgcttctc aaagagcctc 720
ctgctctcag cctcaatcct ggtcctctgg atgctccaa gctcccagg agctctctac 780
atccagaaga ttccagagca gcctcaaaag aaccaggacc ttctcctgtc agtccagggt 840
gtcccagaca ccttccagga ctccaactgg taccctgggg aggagacgta cggaggcacg 900
aggctattta cctacatccc tgggatacaa cggcctcaga gggatggcag tgccatggga 960
cagcgagaca tegtgggctt cccaatggt tccatgtctg tgcgcgcgc ccagcctaca 1020
gacagtggca cctaccaagt agccattacc atcaactctg aatggactat gaaggccaag 1080
actgaggtcc aggtagctga aaagaataag gagctgcca gtacacacct gccaccaaac 1140
gctgggatac tggcgccac catcattgga tctcttgctg ccggggccct tctcatcagc 1200
tgcatcgct atctcctggg gacaaggaa tggaggggccc agagccacag gatggcgacc 1260
acagagaagc cagaattggg ccctgctcat gatgctgggt acaacaacat ctatgaagtg 1320
atgccctctc cagtcctcct ggtgtcccc atcagtga caaggtccat aaaccagacc 1380
cgccccctgc ccacaccccc acacctgac gcggagcaga gaaccaccag taccaggacc 1440
tgctaaaccc cgacctgcc cctactgcc agctgggtgcc aacttcctga tgggtcctgg 1500
gccaggccag ccaggggaga gacaaggccc cagccctcct ctgggagcct cacacctgag 1560
accagcagga caaggccatt gggggctgtg gggccgatga ggtggactca gccaaagact 1620
cagcagcaca tggggcaggt gtccctggcag ggggacagga gactgtaaca ggcccaggtc 1680
cttgtgcagc cctgaatgc acgcccgcct tgggtctgtt ccttcaagca agctggcctg 1740
ggccatgtgc ctgtgaaagg caggctctgg cccctttcca tgccaaagtc cccaagatc 1800
tggatatctg gggacaagat ggtggcctca ggccctgctc ccaggcagtt ggctgggctc 1860
ccaactgtct gtccatcatg cctaccccc actccactag tgaccctcag agtcttctcc 1920
ccttaggaca aggcagacac cccacctatg gggcctcagg tggcagagag gccagcctc 1980
acaggcctgt gggccacac accagtccca ccaaggctgac cagggctgct ggacccttc 2040
cctgttcagg caggcccagc cctctcaga acctgctgcc agctgctggg cttggccccc 2100
accctgaate ttactgagtc cctctgggca gcagctccct tctccacccc accccagcac 2160
ccgtcccaaa tgtggcctca gcttgcctc cccctcccca aactatgcat tcattcagca 2220
ataaatgagc ctttgcctga tgccagacc agttctaggc tcttgacagc ctggtagaaa 2280
gcaaaacaaa aactcccgtt tcccagagg gtcacttggc aggggaaaga atcaggaaat 2340
aaacaaat 2348

<210> 7
<211> 2243
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 1929823CB1

<400> 7
ctaaaacaga agaattcttag cactgagata agggagaacc tgtcagagct ccgtcaggag 60
aattccaagt tgacgttcaa tcagctgctg acccgcttct ctgcctacat ggtagcctgg 120
gttgtctcta caggagtggc catagcctgc tgtgcagccg tttattacct ggctgagtac 180
aacttagagt tctgaagac acacagtaac cctggggcgg tgcgtgtact gcctttcgtt 240
gtgtcctgca ttaatctggc cgtgccatgc atctactcca tgttcaggct tgtggagagg 300

WO 00/52161

PCT/US00/05153

```
tacgagatgc caccggcacga agtctacgtt ctctgatcc gaaacatctt tttgaaaata 360
tcaatcattg gcattctttg ttactattgg ctcaacaccg tggccctgtc tgggtgaagag 420
tggtgggaaa ccttcattgg ccaggacatc tacgggctcc ttctgatgga ttttgtgttc 480
tcttttagtca attccttcct gggggagttt ctgaggagaa tcattgggat gcaactgata 540
acaagtcttg gccttcagga gtttgacatt gccaggaacg ttctagaact gatctatgca 600
caaaactctg tgtggattgg catctctctc tgcccctgtc tggcccttat ccaaagatt 660
atgcttttca tcatgttcta ctccaaaaat atcagcctga tgatgaattt ccagcctccg 720
agcaaagcct ggcgggcctc acagatgatg actttcttca tcttcttgc ttttttccca 780
tccttcaccg gggctctgtg caccctggcc atcaccatct ggagattgaa gccttcagct 840
gactgtggcc cttttcgagg tctgectctc ttcattcaact ccattctacag ctgagtcgag 900
accctaagta caccggcctg ctacctgtgg gttgtttgga tctatcgga cctcatttga 960
agtgtgcact tctttttcat cctcacctc attgtgctaa tcatcaccta tctttactgg 1020
cagatcacag aggggaaggaa gattatgata aggtgctcc atgagcagat cattaatgag 1080
ggcaaagata aaatgttct gatagaaaaa ttgatcaagc tgcaggatat ggagaagaaa 1140
gcaaacccca gctcacttgt tctggaaagg agagaggtgg agcaacaagg ctttttgcac 1200
ttgggggaac atgatggcag tcttgacttg cgatctagaa gatcagttca agaaggtaat 1260
ccaagggcct gatgactctt ttggtaacca gacaccaatc aaataagggg aggagacgaa 1320
aatggaatga tttcttccat gccacctgtg cctttaggaa ctgcccagaa gaaaatccaa 1380
ggcttttagc aggagcgga actgactacc atgtaattat caaagtaaaa ttgggcattc 1440
catgctatct ttaatacctg gattgctgat ttttcaagac aaaatacttg gggttttcca 1500
ataaagattg ttgtaatat gaaatgagcc tacaaaaacc taggaagaga taactaggga 1560
ataatgtata ttatcttcaa gaagtgtgtg caggaatgat tggttcttag aaatctctcc 1620
tgccagactt cccagacctg gcaaagggtt agaaactgtt gctaagaaaa gtggccatc 1680
ctgaataaac atgtaatact ccagcaggga tatgaagcct ctgaattgta gaacctgcat 1740
ttattttgtg ctttgaacta aagacatccc ccatgtccca aaggtggaat acaaccagag 1800
gtctcatctc tgaactttct tgcgtactga ttacatgagt ctttgagtc ggggatggag 1860
gaggttctgc cctgtgagg tgttatatat gaccatcaaa gtccctacgc aagctagctt 1920
tgcagtggca gtaccgtagc caatgagatt tatccgagac gcgattattg ctaattggaa 1980
attttcccaa taccaccacc tgatgacttg aaatataatc agcgctggca atttttgaca 2040
gtctctacgg agactgaata agaaaaaaga aaagaaaaga aattagctgg gtgcatggc 2100
ttatgctgtt aatcccgcca ctttgggagg ctgaggcaag cggatcactt aatgtcagga 2160
gttcaagacc agcctggcca acatggtgaa acccctctc tactaaggat aaaaaaactg 2220
gctgggcgtg gtggtacatg cct 2243
```

<210> 8
 <211> 630
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 2050566CB1

```
<400> 8
taaactggga gctgtacgtg gatgggagca gcttcaccaa cctctgcaaa gtgactcaga 60
aaaagccctg ctccagtcac acccggaagc tgactgggcc acgcatggcc gaagcatgag 120
gaagctcatc gtttagattca tttttcttaa attttggact tatacagtaa gggcttcaac 180
taaccttact caaaatgggg actgttccca gtgtatttat caggtcaccg aagtaggaca 240
gcaaattaaa acaatcttct tgttctatag ttattatgaa tgtatggaaa cattaaaaga 300
aacttgtttg tataatgcca ctcagtacaa ggtatgtagc ccgagaaatg accgacctga 360
tgcgtgttat aaccatctg agcccgctgc aaccaccgtt tttgaaataa gaactggcct 420
tttgctaggt gatacaagta aaataataac tagaacagaa gaaaaagaaa tccccaagca 480
aataacttta agatttgatg cttgtgcagc catataatag aaaaagctag aaataggatg 540
tggttctctt aactgagaaa ggagctaaag agtagaaaaa aaatatgttt gtcattagtc 600
aggggtttgt aaaaattgtc ctattgccag 630
```

<210> 9
 <211> 1790
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> misc_feature
 <223> Incyte ID No: 2479425CB1

WO 00/52161

PCT/US00/05153

```

<400> 9
tctgggagct cacagtttat ttagggagat aggtatataca caggaaacag taacaagggc 60
tgccagctcc cagccctccc tcaactccagc tgttctctcc agttcttcca gatgtcctcc 120
aggtgtctgc tgccccccca gggccccgag gccgcccaggc cccaacctca cccccacgca 180
tgacgggtgca tgaggggcag gagctggcac tgggctgcct ggcgaggaca agcacacaga 240
agcacacaca cctggcagtg tcctttgggc gatctgtgcc cgaggcacca gttgggcggg 300
caactctgca ggaagtgggt ggaatccggt cagacttggc cgtggagggt ggagctccct 360
atgctgagcg attggctgca ggggagcttc gtctgggcaa ggaagggacc gatcgggtacc 420
gcatggtagt aggggggtgcc caggcagggg acgcaggcac ctaccactgc actgccgctg 480
agtggattca ggatcctgat ggcagctggg ccagatttgc agagaaaagg gtcgctctgg 540
cccacgtgga tgtgcagacg ctgtccagcc agctggcagt gacagtgggg cctgggtgaac 600
gtcggatcgg cccaggggag cccttggaac tgcgtgtgcaa tgtgtcaggg gcacttcccc 660
cagcaggccg tcatgctgca tactctgtag gttgggagat ggcacctgcy ggggcacctg 720
ggcccgcccg cctggtagcc cagctggaca cagaggggtg gggcagcctg ggccctggct 780
atgagggccg acacattgcc atggagaagg tggcatccag aacataccgg ctacggctag 840
aggtgtccag gcctgggtgat gcgggcacct accgctgcct cgccaaagcc tatgttcgag 900
gggtctgggac ccggcttcgt gaagcagcca gtgcccgttc ccggcctctc cctgtacacg 960
tgccggagga aggtgtgggt ctggaggctg tggcatggct agcaggaggc acagtgtacc 1020
gcggggagac tgccctccctg ctgtgcaaca tctctgtgcy ggggtggccc ccaggactgc 1080
ggctggccgc cagctgggtg gtggagcgac cagaggacgg agagctcagc tctgtccctg 1140
cccagctggg ggggtggcgt ggccaggatg gtgtggcaga gctgggagtc cggcctggag 1200
gagccctgt cagcgtagag ctgggtgggc cccgaagcca tcggctgaga ctacacagct 1260
tgggggccga ggatgaaggc gtgtaccact gtgccccag cgctgggtg tacccttaca 1320
actacagctg gtaccaggcg ggcagtgcc gctcagggcc tgttacagtc tacccttaca 1380
tgcctgccct ggacacctta tttgtgcttc tgctgggtggg tacaggggtg gccctagtca 1440
ctgggtccac tgccttggg accatcactt cgactgtctt ccggcccagc tccaagccct 1500
gateccctac tccccagggt ctctccctct gtccactctt cctttaattt atttgacctc 1620
cctctgggtg cctggacacc cgtgcctccc ctccccact ccttccctcc caagccctc 1680
ccactaccca gaatgggaga atctcttagg gatectatag ggaggccatt tcctgtctg 1740
cctctggctt tctctcttg tgaataaact tgttttataa aaaaaaaaaa 1790
gaattagttt ttctaaaatg

```

```

<210> 10
<211> 651
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3073609CB1

```

```

<400> 10
ggaagagacg gcgctggaac ccatggacac ggcgtatccc cgcgaggaca cccggggcccc 60
cacgcccagc aaggccggtg cccacacagc cctcacactg gcggccccgc accccccgcc 120
tcgagaccac ttgatctggt cgggtgttcag caccctctac ctgaatctgt gttgcctcgg 180
cttcttgccg ctggcctact ccatcaaggc ccgagatcag aaggtgggtg gtgacctgga 240
agcggccccg cgttttgggt ccaaagccaa gtgctacaac atcctggccg cgatgtggac 300
gctgggtgcc cactgctgc tcctgggggt ggtgggtgact ggtgccctgc acctggcccc 360
gctggccaag gactctgccg ccttcttcag caccaagttt gatgacgcgg actatgactg 420
acaggctggg tcctgatctg gggcactagc cccaggacac tgaccccagg ctgctgcccc 480
tgggggccaa tactgactcc ccggagcctg gccctccttc tgtggggcct ccatecctgc 540
cccatecctg tcctggggcc ctccagcccc aacatgggca cctaaggctg aaccagtcag 600
accccggggt cttcaccccta acccgagagt tcccggggcc taactctgcc c 651

```